CereGate

CereGate is a software-based company operating in the Computer-Brain Interface space. Its mission is to develop new methods of interacting with the human brain through cutting-edge technology, enabling patients with neurological disorders or sensory deficits to adapt and improve their condition independently, thereby increasing patient independence and quality of life.

CereGate's core offering is a unique software platform that relays information to the human brain, facilitating neuromodulation therapy. This software-first approach sets CereGate apart from traditional hardware-based neuromodulation solutions. The company's technology works by sending signals that the brain can quickly perceive and interpret, akin to braille for the brain, without requiring conscious effort from the patient.

One of CereGate's key applications is FOG-LIGHTS, a deep brain stimulation therapy for treating freezing of gait in Parkinson's patients, which received FDA Breakthrough designation. The company has also launched a clinical trial for this application in the US. CereGate is now accelerating the development of a second generation of applications focused on indications treated through spinal cord stimulation neuromodulation platforms, targeting the largest segment of the growing neuromodulation market.

As of January 2022, CereGate secured additional financing from investors like 468 Capital and re.Mind Capital to expand its team and further develop its platform, with the aim of making multiple clinical solutions based on its technology available within 1-2 years.